MediWound said Santyl is currently the market leader in enzymatic debridement products for wound care, with annual US sales in excess of $360M. A Phase 3 study of EscharEx is expected to begin in ...

SANTYL, now on a larger, global scale. We are confident that EscharEx will demonstrate superior efficacy, addressing critical unmet needs in enzymatic debridement for patients with chronic wounds." ...